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an appropriate choice for a control exists. Young children are atepatitis B
Wenote thecommentsofDr.Aaby [1]on4March2009regarding
he use of control vaccinations in our recent studies of RTS,S/AS01E
n 5–17-month-old children [2] and RTS,S/AS02D combined with
he EPI schedule in young infants [3].
Dr. Aaby and co-workers are concerned that the apparent reduc-
ion in severe adverse events (SAEs) in the RTS,S groups may
epresent an adverse consequence of the control vaccines (rabies
nd hepatitis B vaccines). To evaluate this hypothesis Dr. Aaaby and
o-workers request: “we hope the authors will report the malaria
able 1
tudy of 5–17-month-old children [2].
RTS,S/AS01E
ll subjects
evere adverse events, per-subject analysis N=447
ny SAE 47
AE in absence of P. falciparum infection 41
neumonia 18
astroenteritis 10
. falciparum infection 7
AE related to vaccination 1
eath 1
oys
evere adverse events, per-subject analysis N=217
ny SAE 22
AE in absence of P. falciparum infection 22
neumonia 10
astroenteritis 5
. falciparum infection 1
AE related to vaccination 0
eath 1
irls
evere adverse events, per-subject analysis N=230
ny SAE 25
AE in absence of P. falciparum infection 19
neumonia 8
astroenteritis 5
. falciparum infection 6
elated to vaccination 1
eath 0
264-410X © 2009 Elsevier Ltd.
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Open access under CC BY license.and non-malaria serious adverse events and vaccine efﬁcacy in the
two trials separately for each sex” [1].
Many parents, the FDA, local regulatory authorities and IRBs,
want children to beneﬁt froma vaccine rather than a placebowhereRabies
Percent (95% CI) N=447 Percent (95% CI)
11 (8–14) 82 18 (15–22)
9 (8–14) 61 14 (11–17)
4 (2–6) 26 6 (4–8)
2 (1–4) 21 5 (3–7)
2 (1–3) 21 5 (3–7)
<1 (0–1) 0 0 (0–1)
<1 (0–1) 1 <1 (0–1)
N=225
10 (7–15) 42 19 (14–24)
10 (7–15) 30 13 (9–18)
5 (2–8) 12 5 (3–9)
2 (1–5) 9 4 (2–8)
<1 (0–1) 10 4 (2–8)
0 (0–1) 0 0 (0–1)
<1 (0–1) 1 <1 (0–1)
N=222
11 (7–16) 40 18 (13–24)
10 (6–15) 31 14 (10–19)
4 (2–7) 14 6 (4–10)
2 (1–5) 12 5 (3–9)
3 (1–6) 11 5 (3–9)
<1 (0–1) 0 0 (0–1)
0 (0–1) 0 0 (0–1)
risk of rabies in East Africa, and the disease is fatal if acquired.
Pre-exposure prophylaxis is not widespread in Kenya and Tanza-
nia, but is of proven beneﬁt [4]. The licensed human diploid-cell
rabies vaccine (rabies vaccine BP, Sanoﬁ-Pasteur) was therefore an
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Table 2
Study of young infants [3].
RTS,S/AS02D Hep B vaccine
All subjects
Severe adverse events, per-subject analysis N=170 Percent (95% CI) N=170 Percent (95% CI)
Any SAE 31 18 (13–25) 42 25 (18–32)
P. falciparum infection 2 1 (0–4) 7 4 (2–8)
SAE in absence of P. falciparum infection 29 17 (12–24) 40 24 (17–31)
Pneumonia 10 6 (3–11) 28 17 (11–23)
Gastroenteritis 8 5 (2–9) 5 3 (1–7)
Anemia 2 1 (0–4) 8 5 (2–9)
Death 0 0 (0–2) 1 <1 (0–3)
Boys
Severe adverse events, per-subject analysis N=79 N=85
Any SAE 16 20 (12–31) 26 31 (21–42)
P. falciparum infection 1 1 (0–7) 6 7 (3–15)
SAE in absence of P. falciparum infection 15 19 (11–29) 24 28 (19–39)
Pneumonia 5 6 (2–14) 19 22 (14–33)
Gastroenteritis 4 5 (1–13) 5 6 (2–13)
Anemia 1 1 (0–7) 6 7 (3–15)
Death 0 0 (0–5) 1 1 (0–6)
Girls
Severe adverse events, per-subject analysis N=91 N=85
Any SAE 15 17 (10–26) 16 19 (11–29)
P. falciparum infection 1 1 (0–6) 1 1 (0–6)
SAE in absence of P. falciparum infection 14 15 (9–25) 16 19 (11–29)
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ppropriate control forRTS,S/AS01Evaccinationof 5–17-month-old
hildren.
In EPI (extended programme of immunisation) schedules chil-
ren are routinely vaccinated against hepatitis B, and it would not
ave been acceptable to withhold this vaccination in the control
roup [5]. RTS,S/AS02D includes the hepatitis B surface antigen. It
aises an antibody response to this antigen in infants [6], and so
eplaces the hepatitis B vaccine that would otherwise have been
art of the EPI schedule. The design of both trials was approved by
RB and regulatory authority review.
Dr. Aaby and co-workers have described non-speciﬁc deleteri-
us effects of inactivated vaccines in Sub-Saharan Africa [7]. In Dr.
aby’s work non-speciﬁc vaccine effects were particularly noted in
irls rather than boys [8]. He therefore proposes we re-analyse our
afety data separately by gender. In 5–17-month-old children the
AE rates by vaccination allocation appeared consistent by girls and
oys (Table 1). In the EPI schedule trial, the difference in SAE rates
y vaccination was more pronounced for boys than girls (Table 2).
he difference in pneumonia SAEs was also more pronounced for
oys.
Efﬁcacy against clinical malaria was 53% (95%CI 28–69) in all
–17-month-old children [2], compared with 63% (95% CI 29–81)
n boys and 41% (95% CI −3 to 67) in girls. Efﬁcacy against ﬁrst
nfection was 65% (95%CI, 21–85) in the EPI study [3], compared
ith 52% (95%CI −40 to 84) in boys and 75% (95%CI 6–93) in
irls.
Our phase II studies were not designed to examine inpatient
orbidity in detail. Phase III studies to clarify these ﬁndings are
nderway. There seems little evidence of a non-speciﬁc effect by
r. Aaby’s proposed analysis, and control vaccinations will be used
n accordance with regulatory authority and IRB advice.
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